Attention to the Unseen

Science reports: One hundred and fifty years after a French neurologist first recognized a case of multiple sclerosis (MS) in a young woman with an unusual tremor, the cause of this devastating disease remains elusive. Now, a study that combed data from regular blood tests of 10 million U.S. soldiers has found the strongest evidence yet that infection with a common virus, Epstein-Barr virus (EBV), dramatically increases a person’s chances of developing the rare disease. The work leaves many questions,…

Read More Read More

Carrie Arnold writes: In the fall of 2019, the world began one of the largest evolutionary biology experiments in modern history. Somewhere near the city of Wuhan in eastern China, a coronavirus acquired the ability to live inside humans rather than the bats and other mammals that had been its hosts. It adapted further to become efficient at spreading from one person to the next, even before the body’s defenses could rise against it. But the evolutionary chess game didn’t…

Read More Read More

The New York Times reports: A spate of new studies on lab animals and human tissues are providing the first indication of why the Omicron variant causes milder disease than previous versions of the coronavirus. In studies on mice and hamsters, Omicron produced less damaging infections, often limited largely to the upper airway: the nose, throat and windpipe. The variant did much less harm to the lungs, where previous variants would often cause scarring and serious breathing difficulty. “It’s fair…

Read More Read More

STAT reports: The Omicron wave in the United States is upon us. If you were fortunate enough to tune out from Covid-19 news over the holidays, you’re coming back to startling reports about record high case counts and, in some places, increases in hospitalizations. The wave will crest, of course; the question is when. For now, experts say, the country still has a ways to go to get through the Omicron surge. Below, STAT outlines what Omicron is already teaching…

Read More Read More

The Wall Street Journal reports: The Food and Drug Administration last week authorized two oral antiviral medicines for the early treatment of Covid-19. But don’t get too excited. The U.S. will still have a meager treatment arsenal this winter. The U.S. has been relying on monoclonal-antibody treatments, but most don’t hold up against the Omicron variant. One, by GlaxoSmithKline and Vir Biotechnology, does better at neutralizing the variant, but supply is limited. Pfizer’s newly authorized antiviral pack Paxlovid will also…

Read More Read More

STAT reports: With the world facing the latest in a seemingly endless stream of coronavirus variants — and with bullish talk from manufacturers about a need for even more vaccine shots — you wouldn’t be alone if you were wondering: Are Covid boosters always going to be a fixture in our future? The simple truth is that, at this point, there’s no definitive answer to that question. But virologists, immunologists, and vaccinologists have opinions that are anchored in an understanding…

Read More Read More

Dhruv Khullar writes: The Covid-19 pandemic, like every pandemic before it, is a story of equilibriums: between viral biology and human immune response; between news of the pathogen and fear of it; between the damage it inflicts and the social, economic, and political choices we make. A disease persists as a pandemic as long as these forces remain in flux; it becomes endemic when the balance is, more or less, set. The morning after Thanksgiving, Americans awoke to an unsettling…

Read More Read More

Bloomberg reports: A two-shot course of Pfizer Inc.’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa. Researchers at the Africa Health Research Institute in Durban issued additional data on a small study released earlier this week. The research considered blood plasma samples from 12 participants. Scientists found omicron resulted in about a 41-fold reduction in levels of neutralizing antibodies produced by people who had…

Read More Read More

The New York Times reports: From the start of the pandemic, the coronavirus seemed to target people carrying extra pounds. Patients who were overweight or obese were more likely to develop severe Covid-19 and more likely to die. Though these patients often have health conditions like diabetes that compound their risk, scientists have become increasingly convinced that their vulnerability has something to do with obesity itself. Now researchers have found that the coronavirus infects both fat cells and certain immune…

Read More Read More

Nature reports: As the world sped towards a pandemic in early 2020, evolutionary biologist Jesse Bloom gazed into the future of SARS-CoV-2. Like many virus specialists at the time, he predicted that the new pathogen would not be eradicated. Rather, it would become endemic — the fifth coronavirus to permanently establish itself in humans, alongside four ‘seasonal’ coronaviruses that cause relatively mild colds and have been circulating in humans for decades or more. Bloom, who is based at the Fred…

Read More Read More